CytoAgents to Present CTO1681 Data Demonstrating Reduced CAR-T Toxicity Without Compromising Efficacy at ESMO 2025
核心洞察
CytoAgents (搜索) will present preclinical data at ESMO Immuno-Oncology Congress 2025 showing that CTO1681 reduces cytokine release syndrome (搜索)-driving cytokines without compromising CAR-T cell anti-tumor activity.
The oral immunomodulator targets inflammation in the tumor microenvironment and mitigates cell therapy-induced toxicities in lymphoma (搜索) patients receiving CAR-T cell therapy.
CTO1681 demonstrated preservation of CD19 (搜索) CAR-T cell expansion and anti-tumor efficacy while reducing inflammatory cytokines associated with cytokine release syndrome (搜索) and immune cell-associated neurotoxicity syndrome (搜索).
CytoAgents (搜索), Inc., a clinical-stage biotechnology company, will present preclinical data demonstrating that its investigational drug CTO1681 can reduce dangerous inflammatory side effects of CAR-T cell therapy without compromising the treatment's cancer-fighting effectiveness. The data will be presented at the European Society for Medical Oncology (ESMO) Immuno-Oncology Congress 2025, taking place December 10-12, 2025 in London.
Novel Approach to CAR-T Safety
CTO1681 is an orally administered immune modulator designed as a steroid-sparing inhibitor of prostaglandin (搜索)-mediated inflammation. The drug specifically targets inflammation in the tumor microenvironment and aims to mitigate cell therapy-induced toxicities frequently observed in lymphoma (搜索) patients receiving CAR-T cell therapy.
The company is currently enrolling patients in a Phase 1b/2a clinical trial evaluating CTO1681 in lymphoma (搜索) patients receiving CAR-T cell therapy who are at risk for inflammatory-driven toxicities.
Preclinical Data Shows Promise
At ESMO, CytoAgents (搜索) will present findings from two non-clinical studies that demonstrate CTO1681's ability to attenuate key cytokines known to drive Cytokine Release Syndrome (搜索) (CRS) without compromising CAR-T cell-mediated tumor killing both in vitro and in vivo.
The studies show that CTO1681 does not interfere with CD19 (搜索) CAR-T cell expansion and anti-tumor activity in vivo while reducing the inflammatory cytokines associated with CRS and immune cell-associated neurotoxicity syndrome (搜索) (ICANS).
"These data suggest CTO1681 could enable safer CAR-T cell therapy administration, support outpatient treatment paradigms and broaden patient access without compromising anti-tumor efficacy," said Teresa Whalen, Chief Executive Officer at CytoAgents (搜索).
Conference Presentations
Two poster presentations will be delivered by Michael Howell, PhD, Founder and President of Mountaineer Biosciences (搜索):
Poster 109P: "CTO1681 Does Not Interfere with CAR-T Cell Anti-Tumor Efficacy In Vivo" Poster 113P: "CTO1681 Attenuates CRS-Driving Cytokines Without Compromising CAR-T Cell-Mediated Tumor Killing In Vitro"
Both presentations are scheduled for Wednesday, December 10, 2025, from 5:15 PM to 6:30 PM GMT at the Queen Elizabeth II Centre's Churchill Room.
Broader Therapeutic Pipeline
Beyond oncology applications, CytoAgents (搜索) plans to expand CTO1681 into additional therapeutic categories including asthma (搜索), chronic obstructive pulmonary disease (搜索) (COPD), and atopic dermatitis (搜索). The company describes CTO1681 as an oral, steroid-sparing immunomodulator for multiple indications driven by cytokine-inducing inflammation.